Brand managers value integrated DM

Share this article:
Over 80% of brand managers believe an integrated direct marketing program is an important part of promoting a brand, with almost half saying it is “extremely important,” according to the results of a recent study conducted by pharmaceutical marketing firm PharmaKinnex.

The study conducted in April 2007 gauged the marketing communications preferences of 21 brand managers and was based on both phone and e-mail interviews with a targeted group of industry marketers.

According to the discussions, over one quarter of the respondents felt their current marketing mix was only performing “reasonably well” or “not well at all.” Forty percent of the respondents said they were doing “very well” or “extremely well.”

As part of the study, brand managers were also asked how they would like to be marketed to. Opinions were split on what brand managers felt was the best approach to help them learn more about integrated marketing approaches. Web, direct mail, and in person presentation were the methods selected most often, the survey found.

“Just like the physicians to which they market, brand managers are busier than ever,” said Camille Macchio, PharmaKinnex, director business development. “Consequently, they prefer Web, brief presentations and direct mail contact, which make the best use of their time.”

The survey results also found that almost three out of four respondents currently employ an integrated direct marketing program in their brand's promotional programs.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...